Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular arrhythmias among patients with ...

Among older adults with frailty, evidence on the benefits and risks of discontinuing antihypertensive drugs is limited. In a multicenter, randomized, controlled trial conducted in France, we ...

Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors ...

The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

The current conceptualization of “well-being” may be antithetical to trainees’ professionalization. Can we, for the sake of both doctors and patients, reclaim agency, belief, and joy in ...

Surgery is the main treatment for early-stage non–small-cell lung cancer (NSCLC), even though recurrence remains common.1 Neoadjuvant chemotherapy has offered a modest survival benefit,2 with ...

A 32-year-old woman presented with fatigue, myalgias, and palpitations. The cardiac rhythm was irregularly irregular, and an electrocardiogram showed findings suggestive of grouped beating. A diagn ...

The landscape for genetically modified organisms is changing, thanks to sharp increases in the amounts and numbers of chemical herbicides applied to GM crops and the classification of two of the mo ...

The benefits of women’s health research haven’t been limited to women. But actions by the Trump administration threaten to dismantle the hard-won progress in this area.

On April 20, 2010, Arizona State University (ASU) agreed to pay $700,000 to 41 members of the Havasupai Indian tribe to settle legal claims that university researchers improperly used tribe members ...

A small-molecule drug proves its mettle in the treatment of spinal muscular atrophy, a disease amenable to intervention at the pre-mRNA level.

An industry-supported center claims that it costs companies $2.6 billion to develop a new drug. But we need a broader-based and more transparent reckoning of research-and-development costs to infor ...